SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRAL DRUGS IN TREATMENT OF CHRONIC HCV EGYPTIAN PATIENTS
ABDELLA, H., EL BREEDY, A., AL-BALAKOSY, A., HEGAZY, G., EL KASSAS, M. (2022). SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRAL DRUGS IN TREATMENT OF CHRONIC HCV EGYPTIAN PATIENTS. EKB Journal Management System, 52(3), 413-424. doi: 10.21608/jesp.2022.278066
HEBA MOHAMED ABDELLA; ASHRAF MOHAMMAD EL BREEDY; AMIRA MAHMOUD AL-BALAKOSY; GHADA ASSEM MOHAMED HEGAZY; MOHAMED MAHMOUD EL KASSAS. "SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRAL DRUGS IN TREATMENT OF CHRONIC HCV EGYPTIAN PATIENTS". EKB Journal Management System, 52, 3, 2022, 413-424. doi: 10.21608/jesp.2022.278066
ABDELLA, H., EL BREEDY, A., AL-BALAKOSY, A., HEGAZY, G., EL KASSAS, M. (2022). 'SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRAL DRUGS IN TREATMENT OF CHRONIC HCV EGYPTIAN PATIENTS', EKB Journal Management System, 52(3), pp. 413-424. doi: 10.21608/jesp.2022.278066
ABDELLA, H., EL BREEDY, A., AL-BALAKOSY, A., HEGAZY, G., EL KASSAS, M. SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRAL DRUGS IN TREATMENT OF CHRONIC HCV EGYPTIAN PATIENTS. EKB Journal Management System, 2022; 52(3): 413-424. doi: 10.21608/jesp.2022.278066

SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRAL DRUGS IN TREATMENT OF CHRONIC HCV EGYPTIAN PATIENTS

Journal of the Egyptian Society of Parasitology
Volume 52, Issue 3, December 2022, Page 413-424  XML PDF (764.87 K)
Document Type: Original Article
DOI: 10.21608/jesp.2022.278066
View on SCiNiTO View on SCiNiTO
Authors
HEBA MOHAMED ABDELLA1; ASHRAF MOHAMMAD EL BREEDY1; AMIRA MAHMOUD AL-BALAKOSY1; GHADA ASSEM MOHAMED HEGAZY2; MOHAMED MAHMOUD EL KASSAS3
1Department of Tropical Medicine, Faculty of Medicine, Helwan University, Cairo, Egypt
2Faculty of Medicine, Ain-Shams University, Cairo 11566, Department of GIT and Hepatology
3Department of Endemic Medicine
Abstract
Emergence of direct antiviral agents (DAAs), and campaign done by the National Committee for
Control of Viral Hepatitis (NCCVH), reduced chronic hepatitis C (CHC) prevalence in Egypt. This
study evaluated the efficacy and safety of used DAAs in affiliated centers from October 2017 to
December 2019. Patients were either started treatment or during follow-up for 1 year after therapy
(EOT). They were divided according to treatment into GI: SOF/DAC for 12 weeks, GII: SOF/DAC/
RBV for 12 weeks, GIII: SOF/SIM for 12 weeks, GIV: SOF/RBV for 24 weeks and GV: SOF/
DAC/RBV for 24 weeks. DAAs were effective in all groups, and adverse effects occurred in 54 patients
(38.6%).
The commonest complications were ascites (n=18) followed by jaundice (n=17) and HCC (n=14).
Patients (97.1%) in GIV complained of adverse effects compared to others with a significant difference
(p<0.001). Hematemesis occurred in one patient in GIV. There was also a significantly higher
proportion of ascites (38.2%) in GIV compared to others (P < 0.01), without significant differences
between groups regarding HCC and renal impairment (RI) (P= 0.316 & 0.758 respectively). Five
treatment experienced patients suffered from side effects. Renal impairment was (12.5%) among interferon
(IFN) experienced and SOF/DAC experienced patients and who were treated among GIV
and GV, hepatic encephalopathy was (12.5%) in IFN experienced and SOF/RBV experienced patients
among GIV or GV, but ascites (6.3%) and jaundice (6.3%) were among GIV. None complained
of hematemesis or HCC.
Keywords
Egypt; Patients; Emergence of direct antiviral agents; CHC; chronic hepatitis C; DAAs
Statistics
Article View: 88
PDF Download: 80